NSE - Delayed Quote INR

COHANCE LIFESCIENCES LTD (COHANCE.NS)

1,004.50
-4.80
(-0.48%)
At close: June 13 at 3:29:57 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
11,975,800
11,975,800
10,513,500
13,311,101
13,070,108
Cost of Revenue
3,052,900
3,052,900
3,150,400
5,861,949
5,722,929
Gross Profit
8,922,900
8,922,900
7,363,100
7,449,152
7,347,179
Operating Expense
5,945,800
5,945,800
3,851,000
2,186,149
1,915,189
Operating Income
2,977,100
2,977,100
3,512,100
5,263,003
5,431,990
Net Non Operating Interest Income Expense
-123,500
-123,500
-74,500
-69,793
-84,589
Pretax Income
3,439,200
3,439,200
4,056,700
5,597,298
6,675,898
Tax Provision
791,500
791,500
1,053,900
1,484,395
2,137,850
Net Income Common Stockholders
2,647,700
2,647,700
3,002,800
4,112,900
4,538,049
Diluted NI Available to Com Stockholders
2,647,700
2,647,700
3,002,800
4,112,900
4,538,049
Basic EPS
10.97
10.52
11.80
16.16
17.83
Diluted EPS
10.93
10.45
11.80
16.16
17.83
Basic Average Shares
254,630.36
251,682.51
254,474.58
254,564.96
254,565
Diluted Average Shares
255,495.48
253,368.42
254,474.58
254,564.96
254,565
Rent Expense Supplemental
--
--
9,743
0
61
Total Expenses
8,998,700
8,998,700
7,001,400
8,048,098
7,638,118
Net Income from Continuing & Discontinued Operation
2,647,700
2,647,700
3,002,800
4,112,900
4,538,049
Normalized Income
2,647,700
2,647,700
3,002,800
3,980,528.45
4,033,538.28
Interest Income
--
--
20,154
58,316
686
Interest Expense
123,500
123,500
74,500
128,109
62,310
Net Interest Income
-123,500
-123,500
-74,500
-69,793
-84,589
EBIT
3,562,700
3,562,700
4,131,200
5,725,407
6,738,208
EBITDA
4,337,600
4,337,600
4,677,200
6,205,271
7,129,180
Reconciled Cost of Revenue
3,052,900
3,052,900
3,150,400
5,861,949
5,722,929
Reconciled Depreciation
774,900
774,900
546,000
464,599
382,550
Net Income from Continuing Operation Net Minority Interest
2,647,700
2,647,700
3,002,800
4,112,900
4,538,049
Total Unusual Items Excluding Goodwill
--
--
472,119
180,146
742,183
Total Unusual Items
--
--
472,119
180,146
742,183
Normalized EBITDA
4,337,600
4,337,600
4,677,200
6,025,125
6,386,997
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
47,774.45
237,672.28
3/31/2022 - 5/8/2025

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KILITCH.NS Kilitch Drugs (India) Limited
454.50
-0.01%
 
MEDICAMEQ.NS Medicamen Biotech Limited
412.75
-1.40%
 
HIKAL.NS Hikal Limited
375.80
-0.88%
 
GLENMARK.BO Glenmark Pharmaceuticals Limited
1,669.70
+1.95%
 
WINDLAS.NS Windlas Biotech Limited
932.55
+0.20%
 
KPL.BO Kwality Pharmaceuticals Limited
1,028.75
+1.86%
 
LINCOLN.NS Lincoln Pharmaceuticals Limited
585.95
-1.92%
 
GUFICBIO.NS Gufic Biosciences Limited
370.65
-0.58%
 
AARTIDRUGS.NS Aarti Drugs Limited
463.75
-2.08%
 
VENUSREM.NS Venus Remedies Limited
457.30
+2.60%